Impact on functionality of the paliperidone palmitate three-month formulation in patients with a recent diagnosis of schizophrenia: a real-world observational prospective study.
Maria Paz Garcia-PortillaAdolfo Benito RuizFelisa Gómez RobinaMarta García DoradoPaola María López RengelPublished in: Expert opinion on pharmacotherapy (2022)
Early introduction of PP3M in the course of schizophrenia is associated with a meaningful benefit in social functioning and at least maintains clinical stability.